These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10935701)

  • 1. Long-term evaluation of proliferative donor antigen-specific reactivity in cadaveric kidney transplant recipients.
    Böhmig GA; Säemann MD; Bergmann M; Watschinger B; Regele H; Windhager T; Mühlbacher F; Hörl WH; Zlabinger GJ
    Transpl Int; 2000; 13(3):187-93. PubMed ID: 10935701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved long-term graft function in kidney transplant recipients with donor antigen-specific hyporeactivity.
    Ferraris J; Tambutti M; Prigoshin N
    Pediatr Transplant; 2007 Mar; 11(2):139-44. PubMed ID: 17300492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that improved late renal transplant outcome correlates with the development of in vitro donor antigen-specific hyporeactivity.
    Reinsmoen NL; Matas AJ
    Transplantation; 1993 May; 55(5):1017-23. PubMed ID: 7684534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organ-specific patterns of donor antigen-specific hyporeactivity and peripheral blood allogeneic microchimerism in lung, kidney, and liver transplant recipients.
    Reinsmoen NL; Jackson A; McSherry C; Ninova D; Wiesner RH; Kondo M; Krom RA; Hertz MI; Bolman RM; Matas AJ
    Transplantation; 1995 Dec; 60(12):1546-54. PubMed ID: 8545888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new in vitro approach to determine acquired tolerance in long-term kidney allograft recipients.
    Reinsmoen NL; Kaufman D; Matas A; Sutherland DE; Najarian JS; Bach FH
    Transplantation; 1990 Nov; 50(5):783-90. PubMed ID: 2146784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor cell induced CD69 expression and intracellular IL-2 and IL-4 production by peripheral blood lymphocytes isolated from kidney transplant recipients.
    Paglieroni TG; Perez R; Katznelson S; Muto K; Chang T; Scott S; MacKenzie MR; Holland PV
    Hum Immunol; 1999 Jan; 60(1):41-56. PubMed ID: 9952026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretransplant donor-specific helper T cell reactivity as a tool for tailoring the individual need for immunosuppression.
    van der Mast BJ; van Besouw NM; de Kuiper P; Vaessen LM; Gregoor PJ; IJzermans JN; van Gelder T; Claas FH; Weimar W
    Transplantation; 2001 Sep; 72(5):873-80. PubMed ID: 11571453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Annual trends and triple therapy--1991-2000.
    Nishikawa K; Terasaki PI
    Clin Transpl; 2001; ():247-69. PubMed ID: 12211788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuing observations on the regulatory effects of donor-specific bone marrow cell infusions and chimerism in kidney transplant recipients.
    Garcia-Morales R; Carreno M; Mathew J; Cirocco R; Zucker K; Ciancio G; Burke G; Roth D; Temple D; Fuller L; Esquenazi V; Eskind L; Kenyon NS; Ricordi C; Tzakis A; Miller J
    Transplantation; 1998 Apr; 65(7):956-65. PubMed ID: 9565101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor-specific hyporeactivity after liver transplantation: prominent decreases in donor-specific cytotoxic T lymphocyte precursor frequencies independent of changes in helper T lymphocyte precursor frequencies or suppressor cell activity.
    de Haan A; van den Berg AP; Hepkema BG; van Dijk E; Haagsma EB; The TH; Slooff MJ; Lems SP; de Leij LF; Prop J
    Transplantation; 1998 Aug; 66(4):516-22. PubMed ID: 9734497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic microchimerism and donor antigen-specific hyporeactivity in lung transplant recipients.
    McSherry C; Hertz MI; Jackson AM; Butters K; Diko M; Matas AJ; Bolman RM; Reinsmoen NL
    Clin Transplant; 1995 Dec; 9(6):442-9. PubMed ID: 8645886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced.
    van Besouw NM; van der Mast BJ; de Kuiper P; Smak Gregoor PJ; Vaessen LM; IJzermans JN; van Gelder T; Weimar W
    Transplantation; 2000 Jul; 70(1):136-43. PubMed ID: 10919590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential mixed lymphocyte culture after kidney transplantation: induction of tolerance or sensitization.
    Creemers P; Du Toit E; Cassidy MJ; Kahn D
    Nephron; 1997; 75(2):166-70. PubMed ID: 9041536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroid withdrawal and donor-specific hyporeactivity after cadaveric renal allotransplantation on maintenance triple therapy.
    Beik AI; Higgins RM; Lam FT; Morris AG
    Nephrol Dial Transplant; 1997 Sep; 12(9):1949-55. PubMed ID: 9306348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
    Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients.
    Garcia-Morales R; Carreno M; Mathew J; Zucker K; Cirocco R; Ciancio G; Burke G; Roth D; Temple D; Rosen A; Fuller L; Esquenazi V; Karatzas T; Ricordi C; Tzakis A; Miller J
    J Clin Invest; 1997 Mar; 99(5):1118-29. PubMed ID: 9062371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft immunologic events in deceased donor kidney transplant recipients with preformed HLA-donor specific antibodies.
    Ixtlapale-Carmona X; Arvizu A; De-Santiago A; González-Tableros N; López M; Castelán N; Marino LA; Uribe-Uribe NO; Contreras AG; Vilatobá M; Morales-Buenrostro LE; Alberú J
    Transpl Immunol; 2018 Feb; 46():8-13. PubMed ID: 28974434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved long-term graft outcome in lung transplant recipients who have donor antigen-specific hyporeactivity.
    Reinsmoen NL; Bolman RM; Savik K; Butters K; Matas AJ; Hertz MI
    J Heart Lung Transplant; 1994; 13(1 Pt 1):30-6; discussion 36-7. PubMed ID: 7513186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of donor-specific mixed lymphocyte culture reactivity to graft function in recipients of cadaveric renal allografts.
    Rashid A; Sengar DP; Harris JE
    Clin Exp Immunol; 1979 Jun; 36(3):521-7. PubMed ID: 158449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.